14-day Premium Trial Subscription Sign Up For FreeGet Free

Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN

$182.50 (0%)

Volume: 0

Closed: Jan 21, 2022

Hollow Logo Score: 0.000

Alexion Pharmaceuticals Stock Forecast

$182.50 (0%)

Volume: 0

Closed: Jan 21, 2022

Score Hollow Logo 0.000

Alexion Pharmaceuticals Stock News NASDAQ:ALXN

Acquisition of Alexion completed

06:43pm, Wednesday, 21'st Jul 2021 CompanyNewsHQ
21 July 2021 13:45 BST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN View post on CompanyNewsHQ : Acquisition of Alexion completed Read more
Related Stocks: ALXN , WORK , XLNX , PFPT , NUAN , WLTW , PPD , KSU , QTS , VAR , RP , GLUU , WIFI , CLGX , PS , Read more
Ultomiris, the successor to Alexion Pharmaceuticals Inc''s (NASDAQ: ALXN ) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing , a whopping 48% Full story available on Benzinga.com Read more
Related Stocks: ALXN , MXIM , IMVT , KSU , INFO , WLTW , NUAN , UFS , PPD , CLGX , AEGN , CUB , PRSP , VAR , RP , Read more
Related Stocks: ALXN , Read more

Moderna Stock, Soon To Join S&P 500, Rockets To Another Record High

04:48am, Saturday, 17'th Jul 2021 Bitcoin Ethereum News
The post Moderna Stock, Soon To Join S&P 500, Rockets To Another Record High appeared on BitcoinEthereumNews.com . Moderna stock rocketed to another record high on Friday on news it will join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion Pharmaceuticals (ALXN). X The swap will occur when Read more
Stocks that traded heavily or had substantial price changes Friday: Moderna Inc., up $26.76 to $286.43. The biotechnology company will replace Alexion in the S&P 500 prior to Read more

Moderna Stock Soon To Join S&P 500 Rockets To Yet Another Record

03:13pm, Friday, 16'th Jul 2021 Investor''s Business Daily
Moderna stock rocketed to another record high Friday on news it would join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion. Read more
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN). The post MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500 appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now It doesnt matter if you have $500 in savings or $5 million. Do this now. Read more

When Will Moderna Be Added to the S&P 500?

01:49pm, Friday, 16'th Jul 2021 The Street
Moderna is joining the S&P 500 on July 21, replacing Alexion Pharmaceuticals. Read more

MRNA Surges to Record High on Plans to Join S&P 500

01:37pm, Friday, 16'th Jul 2021 Schaeffers Investment Research
Moderna stock is set to join the benchmark on July 21, replacing Alexion Pharmaceuticals Read more
Summary List Placement Shares of Moderna spiked 8% to record highs on Friday after it was selected to be added to the S&P 500 index. The mRNA biotech platform will replace Alexion Pharmaceuticals in the index shake-up. Shares of Moderna eclipsed a $100 billion valuation for the first time on Thursday. Sign up here for our daily newsletter, 10 Things Before the Opening Bell . Moderna jumped as much as 8% on Friday after it was selected to be included in the S&P 500 index. The mRNA biotech platform hit record highs and eclipsed a $100 billion valuation for the first time ever on Thursday. Moderna has seen an ongoing surge ever since it announced successful COVID-19 vaccine data late last year. Moderna will replace Alexion Therapeutics in the market-cap weighted index. Alexion is being acquired by AstraZeneca , pending final closing conditions. Given Moderna''s current market valuation of about $112 billion, the company will have a 0.30% weighting in the popular US Large Cap index. The S&P 500 index switch will occur just before trading on July 21. Read more
Alexion Pharmaceuticals Inc (NASDAQ: ALXN ) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met its primary endpoint, with a statistically significant change in MG-ADL score from baseline through Week 26 for Ultomiris compared to placebo (-3.1 versus -1.4). Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) Full story available on Benzinga.com Read more

Why Moderna Shares Are Rallying Today

11:20am, Friday, 16'th Jul 2021 Benzinga
Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA ), which ended Thursday''s session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday. Standard & Poor''s announced late Thursday Moderna will join the S&P 500 Index, effective before the market opens Wednesday, July 21. Moderna will replace Alexion Pharmaceuticals, Inc. (NASDAQ: Full story available on Benzinga.com Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE